Show simple item record

dc.contributor.authorPiccirillo, SG
dc.contributor.authorSpiteri, I
dc.contributor.authorSottoriva, A
dc.contributor.authorTouloumis, A
dc.contributor.authorBer, S
dc.contributor.authorPrice, SJ
dc.contributor.authorHeywood, R
dc.contributor.authorFrancis, N-J
dc.contributor.authorHowarth, KD
dc.contributor.authorCollins, VP
dc.contributor.authorVenkitaraman, AR
dc.contributor.authorCurtis, C
dc.contributor.authorMarioni, JC
dc.contributor.authorTavaré, S
dc.contributor.authorWatts, C
dc.date.accessioned2018-11-19T12:04:37Z
dc.date.issued2015-01-01
dc.identifier.citationCancer research, 2015, 75 (1), pp. 194 - 202
dc.identifier.issn0008-5472
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2941
dc.identifier.eissn1538-7445
dc.identifier.doi10.1158/0008-5472.can-13-3131
dc.description.abstractGlioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the sub-ependymal zone (SEZ) of patients with glioblastoma. Histologic analysis and genomic characterization revealed that the SEZ harbors malignant cells with tumor-initiating capacity, analogous to cells isolated from the fluorescent tumor mass (T). We observed resistance to supramaximal chemotherapy doses along with differential patterns of drug response between T and SEZ in the same tumor. Our results reveal novel insights into glioblastoma growth dynamics, with implications for understanding and limiting treatment resistance.
dc.formatPrint-Electronic
dc.format.extent194 - 202
dc.languageeng
dc.language.isoeng
dc.publisherAMER ASSOC CANCER RESEARCH
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectEpendyma
dc.subjectCell Line, Tumor
dc.subjectHumans
dc.subjectGlioblastoma
dc.subjectBrain Neoplasms
dc.subjectDrug Resistance, Neoplasm
dc.subjectNeoplastic Stem Cells
dc.subjectNeural Stem Cells
dc.titleContributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.
dc.typeJournal Article
rioxxterms.versionofrecord10.1158/0008-5472.can-13-3131
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2015-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer research
pubs.issue1
pubs.notes6 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Evolutionary Genomics & Modelling
pubs.publication-statusPublished
pubs.volume75
pubs.embargo.terms6 months
icr.researchteamEvolutionary Genomics & Modelling
dc.contributor.icrauthorSpiteri Sagastume, Maria
dc.contributor.icrauthorSottoriva, Andrea


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record